Antitumor effects and molecular mechanisms of action of natural products in ovarian cancer (Review)
- Authors:
- Yun-Bo Yan
- Qing Tian
- Ji-Fang Zhang
- Ying Xiang
-
Affiliations: Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei 434023, P.R. China - Published online on: August 20, 2020 https://doi.org/10.3892/ol.2020.12001
- Article Number: 141
-
Copyright : © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Duska LR and Kohn EC: The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol. 28 (Suppl_8):viii8–viii12. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Weidle UH, Birzele F, Kollmorgen G and Rueger R: Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics. 13:407–423. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tan DS, Agarwal R and Kaye SB: Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7:925–934. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cho KR and Shih Ie M: Ovarian cancer. Annu Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Piccart MJ, Lamb H and Vermorken JB: Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol. 12:1195–1203. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang SF, Wang XY, Fu ZQ, Peng QH, Zhang JY, Ye F, Fu YF, Zhou CY, Lu WG, Cheng XD, et al: TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer. Autophagy. 11:225–238. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang MF, Lou YL, Liu SS, Wang SS, Yin CH, Cheng XH and Huang OP: Capn4 overexpression indicates poor prognosis of ovarian cancer patients. J Cancer. 9:304–309. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
De A, De A, Papasian C, Hentges S, Banerjee S, Haque I and Banerjee SK: Emblica officinalis extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors. PLoS One. 8:e727482013. View Article : Google Scholar : PubMed/NCBI | |
|
Farzaei MH, Bahramsoltani R and Rahimi R: Phytochemicals as adjunctive with conventional anticancer therapies. Curr Pharm Des. 22:4201–4218. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Prasad S and Aggarwal BB: Turmeric, the Golden Spice: From traditional medicine to modern medicine. In Herbal Medicine: Biomolecular and Clinical Aspects. Benzie IFF and Wachtel-Galor S: Boca Raton (FL): 2011, View Article : Google Scholar | |
|
Zhou H, Beevers CS and Huang S: The targets of curcumin. Curr Drug Targets. 12:332–347. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Dobbin ZC and Landen CN: The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Salakou S, Kardamakis D, Tsamandas AC, Zolota V, Apostolakis E, Tzelepi V, Papathanasopoulos P, Bonikos DS, Papapetropoulos T, Petsas T, et al: Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo. 21:123–132. 2007.PubMed/NCBI | |
|
Yu Z, Wan Y, Liu Y, Yang J, Li L and Zhang W: Curcumin induced apoptosis via PI3K/Akt-signalling pathways in SKOV3 cells. Pharma Biol. 54:2026–2032. 2016. View Article : Google Scholar | |
|
Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA and Hoskin DW: Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog. 49:13–24. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Saydmohammed M, Joseph D and Syed V: Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem. 110:447–456. 2010.PubMed/NCBI | |
|
Seo JH, Jeong KJ, Oh WJ, Sul HJ, Sohn JS, Kim YK, Cho DY, Kang JK, Park CG and Lee HY: Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: Their inhibition by curcumin. Cancer Lett. 288:50–56. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Capiod T: Cell proliferation, calcium influx and calcium channels. Biochimie. 93:2075–2079. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Seo JA, Kim B, Dhanasekaran DN, Tsang BK and Song YS: Curcumin induces apoptosis by inhibiting Sarco/endoplasmic reticulum Ca2+ ATPase activity in ovarian cancer cells. Cancer Lett. 371:30–37. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kinose Y, Sawada K, Nakamura K and Kimura T: The role of microRNAs in ovarian cancer. Biomed Res Int. 2014:2493932014. View Article : Google Scholar : PubMed/NCBI | |
|
Du Z and Sha X: Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growth via up-regulating miR-551a. Tumour Biol. 39:10104283176943022017. View Article : Google Scholar : PubMed/NCBI | |
|
Meunier L, Puiffe ML, Le Page C, Filali-Mouhim A, Chevrette M, Tonin PN, Provencher DM and Mes-Masson AM: Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Transl Oncol. 3:230–238. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Pan Y, Li X, Zhang X, Xue Y, Wang T, Zhao S and Hou Y: Dihydroartemisinin and curcumin synergistically induce apoptosis in SKOV3 cells via upregulation of MiR-124 targeting Midkine. Cell Physiol Biochem. 43:589–601. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S and Muramatsu T: Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res. 61:8486–8491. 2001.PubMed/NCBI | |
|
Zhao SF, Zhang X, Zhang XJ, Shi XQ, Yu ZJ and Kan QC: Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells. Asian Pac J Cancer Prev. 15:3363–3368. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhan L, Zhang Y, Wang W, Song E, Fan Y, Li J and Wei B: Autophagy as an emerging therapy target for ovarian carcinoma. Oncotarget. 7:83476–83487. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Boutouja F, Stiehm CM and Platta HW: mTOR: A cellular regulator interface in health and disease. Cells. 8:182019. View Article : Google Scholar | |
|
Liu LD, Pang YX, Zhao XR, Li R, Jin CJ, Xue J, Dong RY and Liu PS: Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells. Arch Gynecol Obstet. 299:1627–1639. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Qu W, Xiao J, Zhang H, Chen Q, Wang Z, Shi H, Gong L, Chen J, Liu Y, Cao R and Lv J: B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway. Int J Biol Sci. 9:766–777. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim I, Xu W and Reed JC: Cell death and endoplasmic reticulum stress: Disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 7:1013–1030. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Alem L and Curry TE Jr: Ovarian cancer: Involvement of the matrix metalloproteinases. Reproduction. 150:R55–R64. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Choe SR, Kim YN, Park CG, Cho KH, Cho DY and Lee HY: RCP induces FAK phosphorylation and ovarian cancer cell invasion with inhibition by curcumin. Exp Mol Med. 50:522018. View Article : Google Scholar : PubMed/NCBI | |
|
Lv J, Shao Q, Wang H, Shi H, Wang T, Gao W, Song B, Zheng G, Kong B and Qu X: Effects and mechanisms of curcumin and basil polysaccharide on the invasion of SKOV3 cells and dendritic cells. Mol Med Rep. 8:1580–1586. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pei H, Yang Y, Cui L, Yang J, Li X, Yang Y and Duan H: Bisdemethoxycurcumin inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressions. Sci Rep. 6:287732016. View Article : Google Scholar : PubMed/NCBI | |
|
Slack-Davis JK, Atkins KA, Harrer C, Hershey ED and Conaway M: Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 69:1469–1476. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cornelison R, Llaneza DC and Landen CN: Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: A Mini-review. Int J Mol Sci. 18:21712017. View Article : Google Scholar | |
|
Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M and Chauhan SC: Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 3:112010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao MD, Li JQ, Chen FY, Dong W, Wen LJ, Fei WD, Zhang X, Yang PL, Zhang XM and Zheng CH: Co-Delivery of Curcumin and paclitaxel by ‘Core-Shell’ targeting Amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer. Int J Nanomedicine. 14:9453–9467. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Liu J, Xu X and Li L: Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol. 79:479–487. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Daleprane JB and Abdalla DS: Emerging roles of propolis: Antioxidant, cardioprotective, and antiangiogenic actions. Evid Based Complement Alternat Med. 2013:1751352013. View Article : Google Scholar : PubMed/NCBI | |
|
Baur JA and Sinclair DA: Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov. 5:493–506. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Liberti MV and Locasale JW: The Warburg effect: How does it benefit cancer cells? Trends Biochem Sci. 41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pavlova NN and Thompson CB: The Emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tan L, Wang W, He G, Kuick RD, Gossner G, Kueck AS, Wahl H, Opipari AW and Liu JR: Resveratrol inhibits ovarian tumor growth in an in vivo mouse model. Cancer. 122:722–729. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gwak H, Kim S, Dhanasekaran DN and Song YS: Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. Cancer Lett. 371:347–353. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Majewska E and Szeliga M: AKT/GSK3β signaling in Glioblastoma. Neurochem Res. 42:918–924. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tino AB, Chitcholtan K, Sykes PH and Garrill A: Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein. J Ovarian Res. 9:842016. View Article : Google Scholar : PubMed/NCBI | |
|
Vergara D, Simeone P, Toraldo D, Del Boccio P, Vergaro V, Leporatti S, Pieragostino D, Tinelli A, De Domenico S, Alberti S, et al: Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst. 8:1078–1087. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lang F, Qin Z, Li F, Zhang H, Fang Z and Hao E: Apoptotic cell death induced by resveratrol is partially mediated by the autophagy pathway in human ovarian cancer cells. PLoS One. 10:e01291962015. View Article : Google Scholar : PubMed/NCBI | |
|
Kroemer G, Marino G and Levine B: Autophagy and the integrated stress response. Mol Cell. 40:280–293. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kang R, Zeh HJ, Lotze MT and Tang D: The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18:571–580. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong LX, Zhang Y, Wu ML, Liu YN, Zhang P, Chen XY, Kong QY, Liu J and Li H: Resveratrol and STAT inhibitor enhance autophagy in ovarian cancer cells. Cell Death Discov. 2:150712016. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Z and Bast RC Jr: The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adh Migr. 7:232–236. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong LX, Nie JH, Liu J and Lin LZ: Correlation of ARHI upregulation with growth suppression and STAT3 inactivation in resveratrol-treated ovarian cancer cells. Cancer Biomark. 21:787–795. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ferraresi A, Phadngam S, Morani F, Galetto A, Alabiso O, Chiorino G and Isidoro C: Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy. Mol Carcinog. 56:1164–1181. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ferraresi A, Titone R, Follo C, Castiglioni A, Chiorino G, Dhanasekaran DN and Isidoro C: The protein restriction mimetic Resveratrol is an autophagy inducer stronger than amino acid starvation in ovarian cancer cells. Mol Carcinog. 56:2681–2691. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mikula-Pietrasik J, Sosinska P and Ksiazek K: Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of alpha5β1 integrins and hyaluronic acid. Gynecol Oncol. 134:624–630. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, Han JW, Kim YM, Kim BK and Lee HY: Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: Their inhibition by resveratrol. Cancer Lett. 258:63–69. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sopo M, Anttila M, Hamalainen K, Kivela A, Yla-Herttuala S, Kosma VM, Keski-Nisula L and Sallinen H: Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. BMC Cancer. 19:5842019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Peng Y, Wang J, Gu A, Li Q, Mao D and Guo L: Effect of autophagy on the resveratrol-induced apoptosis of ovarian cancer SKOV3 cells. J Cell Biochem. Nov 18–2018.(Epub ahead of print). | |
|
Nessa MU, Beale P, Chan C, Yu JQ and Huq F: Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res. 32:53–59. 2012.PubMed/NCBI | |
|
Engelke LH, Hamacher A, Proksch P and Kassack MU: Ellagic acid and resveratrol prevent the development of cisplatin resistance in the epithelial ovarian cancer cell line A2780. J Cancer. 7:353–363. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nag SA, Qin JJ, Wang W, Wang MH, Wang H and Zhang R: Ginsenosides as anticancer agents: In vitro and in vivo activities, Structure-activity relationships, and molecular mechanisms of action. Front Pharmacol. 3:252012. View Article : Google Scholar : PubMed/NCBI | |
|
Ahuja A, Kim JH, Kim JH, Yi YS and Cho JY: Functional role of ginseng-derived compounds in cancer. J Ginseng Res. 42:248–254. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Liu T, Zhao L, Chen W, Hou H, Ye Z and Li X: Ginsenoside 20(S)Rg3 inhibits the Warburg effect through STAT3 pathways in ovarian cancer cells. Int J Oncol. 46:775–781. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng X, Zhou Y, Chen W, Chen L, Lu J, He F, Li X and Zhao L: Ginsenoside 20(S)-Rg3 prevents PKM2-targeting miR-324-5p from H19 sponging to antagonize the Warburg effect in ovarian cancer cells. Cell Physiol Biochem. 51:1340–1353. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Wang L, Chen W, Wang Y, Zhen S, Chen H, Cheng J, Zhou Y, Li X and Zhao L: miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells. Arch Biochem Biophys. 661:1–9. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bian S, Zhao Y, Li F, Lu S, Wang S, Bai X, Liu M, Zhao D, Wang J and Guo D: 20(S)-Ginsenoside Rg3 promotes HeLa cell apoptosis by regulating autophagy. Molecules. 24:36552019. View Article : Google Scholar | |
|
Zheng X, Chen W, Hou H, Li J, Li H, Sun X, Zhao L and Li X: Ginsenoside 20(S)-Rg3 induced autophagy to inhibit migration and invasion of ovarian cancer. Biomed Pharmacother. 85:620–626. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Xi W, Li X, Sun H and Li Y: Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy. Bioorg Med Chem. 27:1145–1158. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu T, Zhao L, Zhang Y, Chen W, Liu D, Hou H, Ding L and Li X: Ginsenoside 20(S)-Rg3 targets HIF-1α to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells. PLoS One. 9:e1038872014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu T, Zhao L, Hou H, Ding L, Chen W and Li X: Ginsenoside 20(S)-Rg3 suppresses ovarian cancer migration via hypoxia-inducible factor 1 alpha and nuclear factor-kappa B signals. Tumour Biol. 39:10104283176922252017.PubMed/NCBI | |
|
Liu D, Liu T, Teng Y, Chen W, Zhao L and Li X: Ginsenoside Rb1 inhibits hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells by regulating microRNA-25. Exp Ther Med. 14:2895–2902. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lengyel E: Ovarian cancer development and metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yun UJ, Lee JH, Koo KH, Ye SK, Kim SY, Lee CH and Kim YN: Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Biochem Pharmacol. 85:1441–1453. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Deng S, Wong CKC, Lai HC and Wong AST: Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition. Oncotarget. 8:25897–25914. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Metodiewa D, Jaiswal AK, Cenas N, Dickancaite E and Segura-Aguilar J: Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic Biol Med. 26:107–116. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Vargas AJ and Burd R: Hormesis and synergy: Pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev. 68:418–428. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hashemzaei M, Delarami Far A, Yari A, Heravi RE, Tabrizian K, Taghdisi SM, Sadegh SE, Tsarouhas K, Kouretas D, Tzanakakis G, et al: Anticancer and apoptosisinducing effects of quercetin in vitro and in vivo. Oncol Rep. 38:819–828. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ren MX, Deng XH, Ai F, Yuan GY and Song HY: Effect of quercetin on the proliferation of the human ovarian cancer cell line SKOV-3 in vitro. Exp Ther Med. 10:579–583. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Gong J, Ding C and Chen G: Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145. Mol Med Rep. 12:3127–3131. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Teekaraman D, Elayapillai SP, Viswanathan MP and Jagadeesan A: Quercetin inhibits human metastatic ovarian cancer cell growth and modulates components of the intrinsic apoptotic pathway in PA-1cell line. Chem Biol Interact. 300:91–100. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Gong W, Yang ZY, Zhou XS, Gong C, Zhang TR, Wei X, Ma D, Ye F and Gao QL: Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3/Bcl-2 axis in ovarian cancer. Apoptosis. 22:544–557. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yamauchi K, Afroze SH, Mitsunaga T, McCormick TC, Kuehl TJ, Zawieja DC and Uddin MN: 3,4′,7-O-trimethylquercetin inhibits invasion and migration of ovarian cancer cells. Anticancer Res. 37:2823–2829. 2017.PubMed/NCBI | |
|
Wang Y, Han A, Chen E, Singh RK, Chichester CO, Moore RG, Singh AP and Vorsa N: The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. Int J Oncol. 46:1924–1934. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z, Liu Y, Liao J, Gong C, Sun C, Zhou X, Wei X, Zhang T, Gao Q, Ma D and Chen G: Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: Involvement of STAT3 signaling. FEBS J. 282:1111–1125. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gong C, Yang Z, Zhang L, Wang Y, Gong W and Liu Y: Quercetin suppresses DNA double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway. Onco Targets Ther. 11:17–27. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yi L, Zongyuan Y, Cheng G, Lingyun Z, Guilian Y and Wei G: Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci. 105:520–527. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ouellet V, Le Page C, Madore J, Guyot MC, Barres V, Lussier C, Tonin PN, Provencher DM and Mes-Masson AM: An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer. Cancer. 110:297–308. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tillhon M, Guaman Ortiz LM, Lombardi P and Scovassi AI: Berberine: New perspectives for old remedies. Biochem Pharmacol. 84:1260–1267. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Xun K, Wang Y and Chen X: A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs. 20:757–769. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Fan J, Ai G, Liu J, Luo N, Li C and Cheng Z: Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol Res. 52:372019. View Article : Google Scholar : PubMed/NCBI | |
|
Nakanishi M and Rosenberg DW: Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 35:123–137. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Cui L, Pan Y, Shao D, Zheng X, Zhang F, Zhang H, He K and Chen L: Berberine inhibits the chemotherapy-induced repopulation by suppressing the arachidonic acid metabolic pathway and phosphorylation of FAK in ovarian cancer. Cell Prolif. 50:e123932017. View Article : Google Scholar | |
|
Zhi D, Zhou K, Yu D, Fan X, Zhang J, Li X and Dong M: hERG1 is involved in the pathophysiological process and inhibited by berberine in SKOV3 cells. Oncol Lett. 17:5653–5661. 2019.PubMed/NCBI | |
|
Zhang Q, Wang X, Cao S, Sun Y, He X, Jiang B, Yu Y, Duan J, Qiu F and Kang N: Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. Biomed Pharmacother. 128:1102452020. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Q, Li L, Zou X, Xu L and Yi P: Berberine attenuated proliferation, invasion and migration by targeting the AMPK/HNF4α/WNT5A pathway in gastric carcinoma. Front Pharmacol. 9:11502018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y and Zhang S: Berberine suppresses growth and metastasis of endometrial cancer cells via miR-101/COX-2. Biomed Pharmacother. 103:1287–1293. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Marverti G, Ligabue A, Lombardi P, Ferrari S, Monti MG, Frassineti C and Costi MP: Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells. Int J Oncol. 43:1269–1280. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Fang Y, Shen H, Xu W and Li H: Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. Acta Biochim Biophys Sin (Shanghai). 45:756–762. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wei ZT, Zhang X, Wang XY, Gao F, Zhou CJ, Zhu FL, Wang Q, Gao Q, Ma CH, Sun WS, et al: PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci. 100:1408–1413. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Q, Qin R, Fang Y and Li H: Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. Cell Physiol Biochem. 36:956–965. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hou D, Xu G, Zhang C, Li B, Qin J, Hao X, Liu Q, Zhang X, Liu J, Wei J, et al: Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death Dis. 8:e30702017. View Article : Google Scholar : PubMed/NCBI | |
|
Xinqiang S, Mu Z, Lei C and Mun LY: Bioinformatics analysis on molecular mechanism of green tea compound epigallocatechin-3-gallate against ovarian cancer. Clin Transl Sci. 10:302–307. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Huh SW, Bae SM, Kim YW, Lee JM, Namkoong SE, Lee IP, Kim SH, Kim CK and Ahn WS: Anticancer effects of (−)-epigallocatechin-3-gallate on ovarian carcinoma cell lines. Gynecol Oncol. 94:760–768. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Landen CN, Li Y, Alvarez RD and Tollefsbol TO: Enhancement of Cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M Arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J Oncol. 2013:8729572013. View Article : Google Scholar : PubMed/NCBI | |
|
Yan C, Yang J, Shen L and Chen X: Inhibitory effect of Epigallocatechin gallate on ovarian cancer cell proliferation associated with aquaporin 5 expression. Arch Gynecol Obstet. 285:459–467. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Liu S, Xu J, Li W, Duan G, Wang H, Yang H, Yang Z and Zhou R: A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells. Cell Death Dis. 8:e31602017. View Article : Google Scholar : PubMed/NCBI | |
|
Tian M, Tian D, Qiao X, Li J and Zhang L: Modulation of Myb-induced NF-kB-STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors. J Cell Physiol. 234:21126–21134. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chan MM, Soprano KJ, Weinstein K and Fong D: Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol. 207:389–396. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Jiang P, Wang P, Yang CS, Wang X and Feng Q: EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer. PLoS One. 10:e01254022015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Jiang P, Wang P, Yang CS, Wang X and Feng Q: Correction: EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer. PLoS One. 10:e01320862015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Landen CN, Li Y, Alvarez RD and Tollefsbol TO: Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp Cell Res. 319:697–706. 2013. View Article : Google Scholar : PubMed/NCBI |
